Trial reportJournal of biopharmaceutical statistics2008
Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Trial report in Journal of biopharmaceutical statistics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.The AAPS journal · 2017Trial
- Pharmacokinetics of oral fludrocortisone in septic shock.British journal of clinical pharmacology · 2016Trial
- Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.Pediatric research · 2016Trial
- Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.Journal of pharmacokinetics and pharmacodynamics · 2016Trial
- Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk.Pediatric research · 2013Trial
- Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.Antimicrobial agents and chemotherapy · 2010Trial
- Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.CPT: pharmacometrics & systems pharmacology · 2022Article
- Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.CPT: pharmacometrics & systems pharmacology · 2021Article
- In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study.Pharmacology research & perspectives · 2020Article
- Model Averaging in Viral Dynamic Models.The AAPS journal · 2020Article
- Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.Clinical pharmacokinetics · 2018Observational
- Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.The AAPS journal · 2018Article
- Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.The AAPS journal · 2015Article
- Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation.European journal of clinical pharmacology · 2013Article
- Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.Clinical pharmacokinetics · 2013Article
- Design of pharmacokinetic studies for latent covariates.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.Clinical pharmacology and therapeutics · 2012Article
- Development of a complex parent-metabolite joint population pharmacokinetic model.The AAPS journal · 2011Article
- A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.British journal of clinical pharmacology · 2011Article
- Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluate by simulation three model-based methods to test the influence of a single nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA) on the empirical Bayes estimates of the individual parameters, likelihood ratio test between models with and without genetic covariate, and Wald tests on the parameters of the model with covariate. Analyses are performed using the FO and FOCE method implemented in the NONMEM software. We compare several approaches for model selection based on tests and global criteria. We illustrate the results with pharmacokinetic data on indinavir from HIV-positive patients included in COPHAR 2-ANRS 111 to study the gene effect prospectively. Only the tests based on the EBE obtain an empirical type I error close to the expected 5%. The approximation made with the FO algorithm results in a significant inflation of the type I error of the LRT and Wald tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.